Palate
发表于 2025-3-30 08:20:19
Pharmacology of the KidneyKD leads to several complications that, if untreated, result in uremia and death. The active vitamin D. calcitriol is substituted. For hyperphosphatemia, phosphate binders are given, for treatment of secondary hyperparathyroidism calcimimetics, for renal anemia epoetin or darbepoetin, and for ADPKD
散布
发表于 2025-3-30 15:58:29
http://reply.papertrans.cn/19/1811/181054/181054_52.png
食物
发表于 2025-3-30 18:32:11
Drugs for Treatment of Respiratory Tract Diseasesd respiratory tract resistance. The therapeutic goal is to normalize these pathophysiological changes. In intermittent asthma, SABAs are administered on demand. In mild asthma, IGCR agonists are added as long-term medication. In moderate asthma, IGCR agonists + LABAs are used. In severe asthma, LTRA
hereditary
发表于 2025-3-30 23:29:10
Drugs for Treatment of Hypertensionious complications including CHD, CHF, stroke, and CKD. However, hypertension can be treated very effectively and economically. The key for therapeutic success is the early onset of treatment, encompassing a healthy lifestyle and judicious use of different drug classes. BP can be decreased via reduc
让你明白
发表于 2025-3-31 04:55:34
Drugs for Treatment of Chronic Heart Failure and Coronary Heart Diseasevous system and RAAS is only a short-term adaptation to this situation. In the long run, remodeling of the blood vessels, the kidney, and the heart takes place, deteriorating CHF. Based on the pathophysiology and clinical studies, β.AR antagonists, ACEIs, AT.R antagonists, and MCRAs are the most imp
CYN
发表于 2025-3-31 07:59:15
http://reply.papertrans.cn/19/1811/181054/181054_56.png
Indent
发表于 2025-3-31 09:27:06
http://reply.papertrans.cn/19/1811/181054/181054_57.png
CORD
发表于 2025-3-31 14:27:44
http://reply.papertrans.cn/19/1811/181054/181054_58.png
灵敏
发表于 2025-3-31 17:40:30
,Butterfield’s Critique of Acton, of therapeutic antibodies and fusion proteins being genetically engineered drugs, inhibiting the function of cytokines, cytokine receptors, integrins, and lymphocyte antigens. However, the high costs of biologicals constitute a pharmacoeconomic problem.